sever
acut
respiratori
syndrom
sar
caus
sar
coronaviru
scv
diseas
appear
guandong
provinc
southern
china
epidem
affect
patient
caus
death
countri
contin
sever
treatment
modal
tri
limit
success
treat
sar
varieti
experiment
drug
develop
type
interferon
suggest
potenti
candid
treat
sar
sever
anim
human
coronavirus
includ
scv
shown
sensit
ifn
vitro
vivo
pilot
clinic
report
show
effect
treatment
sar
patient
review
summaris
antivir
activ
ifn
special
regard
sar
review
publish
clinic
experiment
data
describ
use
ifn
sar
reprint
order
pleas
contact
reprint
ashleypubcom
sever
acut
respiratori
syndrom
sar
recent
recognis
febril
sever
lower
respiratori
ill
caus
infect
novel
coronaviru
sar
coronaviru
scv
sinc
first
report
outbreak
atyp
pneumonia
guandong
provinc
china
late
success
similar
outbreak
wide
report
march
onward
hong
kong
canada
countri
around
world
affect
patient
caus
least
death
updat
inform
found
overal
mortal
rate
vari
profoundli
age
sar
affect
rel
children
gener
appear
milder
paediatr
age
group
contrast
mortal
rate
elderli
high
number
strategi
use
treatment
prevent
sar
includ
empir
antibiot
therapi
intraven
oral
ribavirin
corticosteroid
oseltamivir
intraven
immunoglobulin
howev
signific
vivo
toxic
ribavirin
limit
antivir
activ
vero
cell
infect
differ
scv
strain
encourag
ribavirin
treatment
patient
infect
scv
recent
result
show
antiscv
effect
ribavirin
depend
cell
line
use
ribavirin
shown
inhibit
scv
replic
fetal
rhesu
cell
moreov
rapid
emerg
epidem
permit
control
studi
conduct
document
efficaci
therapi
hyperimmunoglobulin
neutralis
antibodi
proteas
inhibitor
fusion
inhibitor
silenc
scv
gene
rna
interfer
natur
product
glycyrrhizin
compon
liquoric
root
interferon
ifn
repres
therapeut
option
treat
sar
patient
ifn
suggest
potenti
candid
treat
review
present
gener
mechan
ifn
activ
special
focu
type
ifn
well
summaris
discuss
publish
data
describ
effect
ifn
scv
replic
vitro
vivo
clinic
set
ifn
consist
multipl
type
speci
one
type
ii
speci
antivir
activ
type
ifn
function
structur
similar
tabl
type
ifn
induc
cell
type
virus
doublestrand
rna
dsrna
cluster
chromosom
consist
sever
gene
pseudogen
one
gene
contrast
mainli
secret
helper
th
lymphocyt
natur
killer
nk
cell
code
singl
gene
chromosom
ifn
mediat
effect
bind
cell
surfac
receptor
thu
activ
member
janu
kinas
jak
famili
activ
jak
phosphoryl
signal
transduc
activ
transcript
stat
famili
transcript
factor
shown
figur
receptor
engag
lead
activ
jakstat
signal
pathway
action
tyrosin
kinas
tyk
protein
kinas
catalys
phosphoryl
event
lead
activ
heterodimeris
stat
protein
mostli
includ
reciproc
homodim
heterocomplex
transloc
nucleu
associ
regulatori
factor
irf
form
ifnstimul
gene
factor
bind
ifnstimul
respons
element
isr
cellular
gene
known
ifnstimul
gene
isg
lead
induc
express
synthesi
isg
product
sequenc
motif
within
isr
also
serv
target
site
irf
whose
action
isrebind
properti
contribut
defin
overal
spectrum
durat
isg
express
gene
product
regul
ifn
primari
effector
ifnmedi
biolog
respons
isg
repres
divers
function
group
rang
gene
encod
immunomodulatori
protein
encod
metabol
regul
oligonucleotid
microarray
studi
fibrosarcoma
cell
line
well
mous
embryon
fibroblast
human
dendrit
cell
treat
ifn
identifi
induc
gene
howev
exact
pattern
induct
vari
depend
cell
type
type
ifn
impress
stimul
transcript
made
difficult
attribut
effect
ifn
particular
gene
product
transcript
isg
induc
ifnindepend
fashion
agent
dsrna
viru
infect
stat
jak
kinas
shown
essenti
dsrnamedi
induct
isg
transcript
factor
known
dsrnaactiv
factor
virusactiv
factor
vaf
implic
dsrnaand
virusmedi
induct
isg
form
transcript
complex
activ
coactiv
creb
bind
protein
cbp
figur
although
viral
infect
cell
ifn
viral
dsrna
contribut
induct
isg
case
mere
bind
viral
envelop
protein
cell
surfac
receptor
trigger
transcript
specif
isg
exampl
isg
induct
ifn
may
recruit
addit
signal
pathway
cell
mitogenactiv
protein
kinas
mapk
phosphatidylinositol
kinas
pathway
ifn
induc
sever
parallel
antivir
pathway
cell
includ
four
major
factor
synthetas
oa
protein
familyribonucleas
l
rnase
l
dsrnadepend
protein
kinas
pkr
mx
protein
rnaspecif
adenosin
deaminas
adar
figur
pathway
specif
particular
group
virus
although
one
pathway
may
control
infect
singl
viru
common
featur
among
antivir
pathway
exclud
mx
protein
requir
dsrna
common
activ
substrat
ifninduc
protein
factor
wherea
oa
pkr
enzym
requir
nonspecif
associ
dsrna
activ
antivir
effect
use
dsrna
substrat
deamin
adenosin
convers
inosin
see
exist
consider
residu
effect
type
ifn
encephalomyocard
viru
emcv
mice
lack
function
rnase
l
pkr
mx
suggest
presenc
addit
pathway
ifninduc
oa
protein
famili
shown
involv
viral
cellular
rna
degrad
concert
latent
rnase
l
three
structur
relat
size
class
oa
enzym
small
medium
larg
encod
three
separ
cluster
gene
within
class
multipl
isozym
differ
carboxyl
termin
region
produc
splice
primari
transcript
enzym
polymeris
atp
oligoadenyl
differ
length
need
activ
dsrna
molecul
activ
latent
ribonucleas
rnase
l
induc
dimeris
synthetasernas
l
system
mediat
antivir
anticellular
action
ifn
degrad
singlestrand
rna
ssrna
antivir
pathway
report
oper
number
virus
includ
import
human
pathogen
hepat
c
viru
vaccinia
hiv
rna
degrad
target
cellular
rna
lead
program
cell
death
apoptosi
program
cell
death
may
prevent
viru
replic
spread
occur
earli
enough
infect
promot
viru
spread
occur
late
rnase
lindepend
action
oa
isozym
caus
apoptosi
process
requir
enzym
activ
mediat
bind
antiapoptot
protein
b
cell
leukaemialymphoma
bcl
bclx
l
therebi
block
action
pkr
repres
ifninduc
serinethreonin
protein
kinas
need
activ
autophosphoryl
ifninduc
pkr
associ
viral
dsrna
becom
activ
howev
agent
heparin
also
activ
pkr
may
interact
sever
cellular
protein
includ
protein
activ
pkr
pact
pact
directli
bind
pkr
activ
independ
dsrna
activ
pkr
may
catalys
phosphoryl
number
substrat
includ
protein
synthesi
initi
factor
thu
prevent
translat
initi
factor
recycl
result
inhibit
protein
synthesi
addit
role
translat
pkr
particip
sever
signal
transcript
pathway
exampl
pkr
contribut
induct
earli
gene
cfo
cjun
plateletderiv
growth
factor
modul
transcript
function
studi
clearli
demonstr
role
pkr
activ
transcript
factor
nuclear
factorkappab
activ
lead
transcript
induct
number
gene
includ
perpetu
ifn
synthesi
induct
parallel
antivir
pathway
clear
pkr
import
mediat
extracellular
stimuli
regul
mani
aspect
cellular
physiolog
includ
regul
cell
growth
differenti
moreov
pkr
might
function
tumour
suppressor
overexpress
lead
apoptosi
via
bclx
l
inhibit
numer
virus
block
pkr
activ
action
use
varieti
biochem
strategi
although
investig
suggest
pkr
dispens
defenc
viru
infect
sever
experi
underlin
crucial
role
mediat
ifn
activ
exampl
overexpress
pkr
lead
inhibit
emcv
replic
dominantneg
pkr
mutant
antisens
pkr
cdna
suppress
antiemcv
action
type
ifn
mice
lack
pkr
predispos
lethal
intranas
infect
usual
innocu
vesicular
stomat
viru
display
increas
suscept
influenza
viru
infect
studi
use
pkr
null
mice
also
shown
kinas
key
compon
host
earli
defenc
system
act
earli
innat
immun
activ
ifn
system
acquir
immun
respons
mx
protein
first
identifi
antiinfluenza
viru
protein
induc
sole
type
ifn
nuclear
cytoplasm
isoform
mx
belong
dynamin
superfamili
gtpase
involv
endocytosi
vesicl
transport
human
mxa
protein
form
larg
oligom
mutant
mxa
fail
form
oligom
devoid
gtpase
activ
mutant
howev
retain
antivir
activ
although
rapidli
degrad
cell
mx
protein
possess
intrins
antivir
activ
requir
cooper
ifninduc
cellular
protein
action
antivir
activ
depend
gtp
bind
well
proteinprotein
interact
viral
protein
result
either
disrupt
viral
rna
synthesi
block
viral
nucleocapsid
transport
uniqu
properti
mx
gtpase
antivir
activ
wide
rang
rna
virus
mous
mx
gene
shown
exert
inhibitori
effect
orthomyxovirus
paramyxovirus
rhabdovirus
togavirus
inhibit
picornaviru
mengo
emcv
replic
observ
mx
pathway
anoth
famili
ifninduc
guanylatebind
protein
gbp
includ
constitut
abund
class
protein
induc
gbp
gtpase
function
bind
hydrolys
gtp
may
mild
antivir
activ
ifninduc
adar
famili
enzym
involv
edit
rna
substitut
adenosin
inosin
cellular
mrna
viral
dsrna
target
transit
decreas
stabil
duplex
rna
convers
stabl
au
base
pair
less
stabl
iu
base
pair
subsequ
code
capac
target
rna
chang
sitespecif
edit
caus
amino
acid
substitut
result
synthesi
protein
alter
function
adar
may
caus
hypermut
number
virus
includ
measl
parainfluenza
type
vesicular
stomat
polyomaviru
hepat
delta
viru
may
lead
inhibit
viru
replic
eventu
persist
infect
given
abil
virus
induc
isg
antivir
activ
surpris
virus
develop
mechan
counteract
stimul
isg
includ
inhibit
almost
aspect
ifn
regulatori
pathway
includ
disrupt
dsrna
ifnjakstat
signal
inhibit
irf
inhibit
other
sensit
anim
human
coronavirus
unrel
scv
ifn
demonstr
vitro
vivo
studi
coronavirus
includ
avian
infecti
bronchiti
viru
murin
hepat
viru
mhv
transmiss
gastroenter
viru
human
coronavirus
sensit
ifn
treatment
although
type
ifn
effect
coronaviru
infect
studi
suggest
type
ifn
may
potent
one
studi
even
stimul
product
infecti
virion
human
coronaviru
strain
human
neuron
cell
potent
mhv
compar
mous
model
recent
work
show
display
strongest
inhibitori
activ
among
sever
potenti
antisar
drug
human
coronaviru
replicas
combin
treatment
ifn
show
synergist
antivir
effect
discuss
previou
section
virus
potenti
induc
ifn
pathway
eventu
lead
ifn
product
infect
cell
abil
induc
cellular
ifn
product
may
modul
viru
infect
demonstr
anim
human
coronavirus
suggest
enteropathogen
potenti
human
coronaviru
strain
pari
may
due
lack
ifn
induct
moreov
leukocyt
children
recurr
respiratori
infect
produc
lower
yield
ifn
stimul
coronaviru
compar
control
cohort
clinic
experi
treatment
coronaviru
infect
ifn
experiment
set
healthi
volunt
treat
intranas
recombin
ifn
iuday
placebo
day
expos
coronaviru
direct
intranas
inocul
eighth
day
treatment
therapi
ifn
shorten
durat
reduc
sever
coronaviru
cold
symptom
suggest
intranas
recombin
may
effect
prophylact
treatment
coronaviru
infect
human
similarli
intranas
spray
ifn
given
day
day
viru
challeng
protect
human
volunt
infect
coronaviru
publish
data
describ
effect
ifn
scv
replic
sar
list
tabl
two
clinic
report
describ
use
treatment
sar
patient
first
studi
describ
treatment
sarspati
guangzhou
capit
guangdong
author
conclud
best
outcom
achiev
combin
highdos
steroid
quinolon
plu
azithromycin
author
opinion
use
result
obviou
antisar
effect
howev
remain
option
part
develop
protocol
second
studi
use
ifn
infergen
intermun
brisban
california
usa
nonnatur
occur
synthet
recombin
type
contain
amino
acid
posit
commonli
observ
amino
acid
nonallel
subtyp
specif
activ
numer
virus
higher
exhibit
agent
indic
higher
antivir
activ
molar
basi
moreov
ifn
induc
nk
cell
activ
potent
compar
preliminari
uncontrol
studi
patient
sar
patient
receiv
singl
treatment
corticosteroid
compar
patient
addit
receiv
ifn
patient
receiv
patient
receiv
use
ifn
result
rapid
resolut
radiograph
lung
abnorm
better
oxygen
satur
level
moreov
ifn
patient
show
less
increas
creatin
kinas
level
rapid
return
lactat
dehydrogenas
normal
level
elev
lactat
dehydrogenas
creatin
kinas
level
suspect
indic
lung
parenchym
damag
associ
poor
prognosi
expert
opin
biol
ther
addit
treatment
ifn
decreas
median
time
peak
lung
involv
ifn
patient
need
supplement
oxygen
shorter
period
case
reemerg
sar
health
canada
alreadi
approv
protocol
trial
includ
steroid
ribavirin
reason
differ
activ
two
studi
remain
specul
zhao
et
al
explicitli
focu
report
paramet
investig
loutfi
et
al
lactat
dehydrogenas
creatin
level
regard
indic
tissu
damag
lung
addit
given
specif
activ
ifn
iumg
dose
ie
iumg
use
loutfi
et
al
higher
iu
use
zhao
et
al
therefor
differ
might
explain
differ
dose
ifn
loutfi
et
al
conclud
antisar
effect
ifn
may
result
treatmentinduc
reduct
viral
load
andor
synergist
immunosuppress
combin
corticosteroid
first
publish
vitro
studi
compar
effect
differ
class
ifn
scv
replic
howev
demonstr
effect
inhibit
scv
replic
far
report
investig
influenc
ifn
scv
replic
human
cell
line
human
colorect
adenocarcinoma
cell
line
investig
exclus
perform
african
green
monkey
kidney
cell
line
vero
effect
recombin
intron
essex
pharma
munich
germani
betaferon
schere
berlin
germani
imukin
boehring
ingelheim
ingelheim
germani
two
differ
viru
strain
hong
kong
compar
vero
cell
pretreat
ec
concentr
compound
need
inhibit
cytopath
effect
control
valu
scv
vero
cell
lower
respect
similar
result
obtain
comparison
antiscv
effect
use
scv
hong
kong
vero
cell
strain
cell
contrast
inhibit
scv
replic
cell
ad
viru
infect
ifn
show
antiscv
effect
although
share
receptor
primarili
induc
protein
may
evok
differ
antivir
activ
due
differ
abil
activ
signal
pathway
differ
impact
specif
gene
induct
comparison
effect
herp
simplex
viru
type
replic
result
superior
antivir
tabl
vero
hong
kong
effect
vero
urbani
inhibit
scv
replic
vero
patient
inhibit
scv
replic
vero
inhibit
scv
replic
vero
scv
human
leukocyt
effect
anim
experi
cynomolg
macaqu
patient
inhibit
sar
symptom
clinic
trial
iud
improv
patient
detect
ifnalfacon
improv
outcom
patient
detect
activ
use
oligonucleotid
array
probe
set
correspond
human
gene
gene
differenti
regul
ifn
alreadi
identifi
pkr
play
essenti
role
replic
inhibit
numer
virus
upregul
human
fibrosarcoma
cell
line
moreov
virus
develop
mechan
order
antagonis
ifninduc
antivir
effect
differ
mechan
includ
interfer
isg
scv
induc
robust
upregul
isg
antivir
activ
mxa
human
cell
upregul
abolish
viru
replic
indic
scv
develop
strategi
counteract
antivir
activ
ifn
natur
effect
possibl
influenc
sensit
scv
differ
ifn
might
help
explain
differ
sensit
scv
second
vitro
studi
report
use
scv
replic
studi
effect
replic
three
scv
isol
urbani
investig
vero
cell
found
specif
activ
time
higher
use
requir
ic
inhibitori
concentr
low
iuml
pretreat
iuml
posttreat
assess
hensley
et
al
system
differ
antiscv
activ
differ
prepar
remain
undetermin
cinatl
et
al
compar
differ
prepar
found
exhibit
similar
effect
compar
antivir
unit
basi
iuml
cultur
medium
howev
higher
specif
activ
compar
may
favour
achiev
maxim
dose
ifn
patient
complet
manuscript
two
public
investig
effect
ifn
scv
replic
vitro
appear
first
report
confirm
alreadi
publish
data
show
inhibit
replic
scv
strain
vero
cell
second
report
describ
screen
clinic
approv
antivir
scv
strain
scv
vero
cell
surprisingli
found
ineffect
contrast
inhibit
scv
replic
explan
result
offer
recent
studi
consid
use
pegyl
recombin
pegintron
scheringplough
corpor
regist
drug
treatment
chronic
hepat
c
candid
drug
sar
therapi
pegyl
attach
inert
polyethlylen
glycol
polym
protein
absorpt
pegyl
molecul
slower
halflif
longer
rate
clearanc
plasma
lower
nativ
molecul
therefor
pegyl
ifn
increas
durat
biolog
activ
pegyl
exhibit
dosedepend
inhibitori
effect
scv
replic
vitro
result
similar
obtain
cinatl
et
al
prophylact
treatment
cynomolg
macaqu
prior
scv
infect
substanti
protect
type
pneumocyt
main
target
cell
scv
infect
macaqu
scv
infect
vivo
use
pegyl
postexposur
protect
type
pneumocyt
less
effect
although
vitro
data
suggest
direct
influenc
pegyl
scv
replic
investig
state
remain
determin
whether
vivo
protect
pegyl
caus
direct
antivir
activ
immunomodulatori
effect
given
superior
antiscv
activ
compar
vitro
vivo
evalu
pegyl
would
high
interest
sever
immunolog
tissu
damag
detect
lung
sar
patient
suggest
immun
respons
inflammatori
process
exacerb
sar
accord
gener
accept
pharmacolog
clinic
intervent
sar
suppress
local
immun
respons
inflammatori
process
use
corticosteroid
therefor
combin
antivir
therapi
antiinflammatori
therapi
promis
therapeut
approach
treatment
sar
influenc
ifn
immun
respons
also
import
clinic
outcom
nearli
phase
innat
adapt
immun
respons
affect
ifn
immunomodulatori
action
type
ifn
includ
enhanc
cytotox
nk
cell
enhanc
express
major
histocompat
complex
class
protein
enhanc
suscept
cell
apoptosi
moreov
ifn
abl
modul
inflammatori
process
experiment
data
concern
influenc
ifn
immun
respons
inflammatori
process
respons
scv
infect
avail
far
howev
knowledg
impact
ifn
immun
respons
scv
sarsassoci
inflammatori
process
highli
import
ration
use
ifn
scv
replic
inhibitor
andor
modifi
immun
respons
inflammatori
process
view
possibl
sar
outbreak
highli
effici
therapeut
strategi
need
experiment
pilot
clinic
data
strongli
suggest
type
ifn
promis
candid
sar
treatment
protocol
may
use
inhibitor
scv
replic
may
also
use
improv
deregul
immun
respons
inflammatori
process
known
contribut
sar
although
major
studi
focu
evalu
clinic
use
author
hand
superior
compar
term
scv
replic
inhibit
fact
elicit
inhibitori
potenti
even
infect
alreadi
occur
underlin
suppos
therapeut
valu
well
prepar
possibl
futur
sar
outbreak
author
strongli
recommend
evalu
improv
therapeut
strategi
involv
prepar
